Stifel lowered the firm’s price target on Definitive Healthcare to $11 from $12 and keeps a Buy rating on the shares after the company announced the resignation of CEO Robert Musslewhite, reiterated Q4 guidance and “put a finer point” on 2024 guidance. The 2024 guidance implies “cyclically depressed” 12-13% EBITDA growth, but the stock remains attractively priced, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DH:
- Definitive Healthcare Announces CEO Transition
- Canaccord downgrades Definitive Healthcare on third workforce reduction
- Definitive Healthcare downgraded to Hold from Buy at Canaccord
- Definitive Healthcare drops after cutting 154 jobs in restructuring
- Definitive Healthcare price target raised to $10 from $7 at Barclays
